<DOC>
	<DOC>NCT01896193</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir plus ribavirin administered for 16 weeks and 24 weeks in participants with chronic genotype 1 (GT1) or genotype 3 (GT3) hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Confirmed chronic genotype 1 or 3 HCV infection HCV treatmentnaive Individuals will have cirrhosis status assessment; liver biopsy may be required. Screening laboratory values within predefined thresholds Use of two effective contraception methods if female of childbearing potential or sexually active male Pregnant or nursing female or male with pregnant female partner Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) Contraindication to ribavirin therapy Excessive alcohol ingestion as defined by protocol History of solid organ transplantation Current or prior history of clinical hepatic decompensation History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>